Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Hepln-13 (Hepln13; Hepln 13) is a novel, orally bioactive and potent hepsin inhibitor (IC50 = 0.33 µM) with potential anticancer activity.
ln Vitro |
Lysis is inhibited by Hepln-13 (10 µM; 2 hours; 293 cells) [1].
|
---|---|
ln Vivo |
HepIn-13 can prevent prostate cancer metastasis and has a dose-dependent inhibitory effect on phenotypes of prostate cancer linked to Hepsin overexpression [1].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: 293 cells Tested Concentrations: 10 µM Incubation Duration: 2 hrs (hours) Experimental Results: Lysis was inhibited. |
References |
Molecular Formula |
C17H13BRN2
|
---|---|
Molecular Weight |
325.2
|
Exact Mass |
324.026
|
CAS # |
64369-13-7
|
PubChem CID |
256658
|
Appearance |
Typically exists as solid at room temperature
|
Density |
1.444g/cm3
|
Boiling Point |
533.3ºC at 760 mmHg
|
Flash Point |
276.4ºC
|
Index of Refraction |
1.688
|
LogP |
5.414
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
2
|
Rotatable Bond Count |
1
|
Heavy Atom Count |
20
|
Complexity |
320
|
Defined Atom Stereocenter Count |
0
|
SMILES |
BrC1=CC=C(C2NC3=CC=CC4C=CC=C(C3=4)N2)C=C1
|
InChi Key |
YSRRRCGJBGQBDM-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C17H13BrN2/c18-13-9-7-12(8-10-13)17-19-14-5-1-3-11-4-2-6-15(20-17)16(11)14/h1-10,17,19-20H
|
Chemical Name |
2-(4-bromophenyl)-2,3-dihydro-1H-perimidine
|
Synonyms |
Hepln13 Hepln 13 Hepln-13
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~192.19 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0750 mL | 15.3752 mL | 30.7503 mL | |
5 mM | 0.6150 mL | 3.0750 mL | 6.1501 mL | |
10 mM | 0.3075 mL | 1.5375 mL | 3.0750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.